Edition:
United States

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Capital Market

4.52USD
10:01am EST
Change (% chg)

$-0.11 (-2.38%)
Prev Close
$4.63
Open
$4.63
Day's High
$4.65
Day's Low
$4.49
Volume
9,336
Avg. Vol
41,567
52-wk High
$11.83
52-wk Low
$4.30

Select another date:

Tue, Dec 5 2017

BRIEF-Redhill Biopharma provides 2017 year-end business update

* REDHILL BIOPHARMA LTD - ‍COST REDUCTION PLAN IS IN PLACE TO GRADUALLY REDUCE AVERAGE QUARTERLY CASH BURN RATE IN 2018 TO APPROXIMATELY $8.5 MILLION​

BRIEF-Redhill biopharma Q3 ‍loss per ordinary share US$0.09

* Redhill Biopharma reports 2017 third quarter financial results

BRIEF-Redhill Biopharma says last patient enrolled in Phase III study with RHB-104 for Crohn’s disease

* Redhill Biopharma announces last patient enrolled in the Phase III study with RHB-104 for Crohn's disease

BRIEF-RedHill Biopharma prices public offering of its American Depositary Shares

* RedHill Biopharma prices public offering of its American Depositary Shares

BRIEF-Redhill Biopharma announces proposed public offering of its American Depositary Shares

* Redhill Biopharma announces proposed public offering of its american depositary shares Source text for Eikon: Further company coverage:

BRIEF-IntelGenx and Redhill Biopharma resubmit Rizaport NDA to FDA

* Intelgenx and Redhill Biopharma resubmit Rizaport new drug application to the FDA

BRIEF-Redhill Biopharma and Intelgenx submit new drug application to FDA for Rizaport® for migraines

* Redhill Biopharma and Intelgenx submit new drug application to FDA for Rizaport® for migraines

BRIEF-RedHill Biopharma receives Notice of Allowance for a new U.S. patent covering RHB-104

* RedHill Biopharma receives Notice of Allowance for a new U.S. patent covering RHB-104

BRIEF-RedHill Biopharma receives FDA Orphan Drug Designation for MESUPRON for pancreatic cancer

* RedHill Biopharma receives FDA Orphan Drug Designation for MESUPRON for pancreatic cancer

RedHill Biopharma's bowel syndrome drug data fails to impress investors

RedHill Biopharma Ltd said on Tuesday its drug to treat diarrhea-predominant irritable bowel syndrome met the main goal in a mid-stage study, but the positive data failed to impress investors, sending its U.S.-listed shares lower.

Select another date: